RxDoctor Payments Data

Elie Lowenstein, MD

Dermatology · Oceanside, NYNPI 1417273988

Payments from drug & device makers

$1,802in general payments, 2019–2025

Across 75 payments — averaging $24.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$674
  • Sanofi$248
  • Amgen$161
  • LEO Pharma Inc.$128
  • Johnson & Johnson$100
  • Regeneron Healthcare Solutions, Inc.$95
  • plus $395 from 10 others

What the payments were for

  • Food & beverage$1,60789%
  • Education$19511%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,802 in reported general payments places this provider in the 40th percentile of 1,151 dermatology providers in New York.

See all dermatology providers in New York

Medicare billing

Part B allowed, 2024
$930,377
Medicare patients
1,374
Services billed
9,684

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Skyrizi PenRisankizumab-Rzaa18$360,142
Dupixent PenDupilumab31$110,102
OtezlaApremilast13$57,617
Clobetasol Propionate150$6,923
Pimecrolimus23$6,017
Fluorouracil74$4,135
Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc121$3,122
Tacrolimus17$2,845
Triamcinolone Acetonide257$2,544
Mometasone Furoate114$2,054
Ketoconazole127$1,970
Clindamycin Phosphate51$1,719
Tretinoin21$1,533
Mycophenolate Mofetil14$1,518
Metronidazole22$1,162

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$161$57,61713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 1,151 dermatology providers in New York.

Other dermatology in Oceanside

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →